Drugs /

ipatasertib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
ipatasertib
NCI Definition [1]:
An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Ipatasertib binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

Clinical Trials

View Clinical Trials for ipatasertib

Ipatasertib has been investigated in 31 clinical trials, of which 25 are open and 6 are closed. Of the trials investigating ipatasertib, 5 are phase 1 (4 open), 9 are phase 1/phase 2 (8 open), 13 are phase 2 (9 open), and 4 are phase 3 (4 open).

HER2 Negative, HER2 Deficient Expression, and ER Negative are the most frequent biomarker inclusion criteria for ipatasertib clinical trials.

Breast carcinoma, malignant solid tumor, and prostate adenocarcinoma are the most common diseases being investigated in ipatasertib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ipatasertib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ipatasertib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ipatasertib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gdc-0068, ipatasertib, (2s)-2-(4-chlorophenyl)-1-(4-((5r,7r)-7-hydroxy-5-methyl-6,7-dihydro-5h-cyclopenta(d)pyrimidin-4-yl)piperazin-1-yl(-3-((propan-2-yl)amino)propan-1-one, rg-7440
Drug Categories [2]:
AKT inhibitors, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
AKT1, AKT2, AKT3
NCIT ID [1]:
C91072

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.